Long Focus Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Long Focus Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.37M	Sell	2,100,000 -6,500,000	-76%	-$20.8M	0.19%	73
2025 Q4	$23.5M	Sell	8,600,000 -516,507	-6%	-$1.19M	0.62%	42
2025 Q3	$19.8M	Sell	9,116,507 -2,703,493	-23%	-$6.38M	0.65%	43
2025 Q2	$20.3M	Buy	11,820,000 +2,569,945	+28%	+$6.39M	0.77%	36
2025 Q1	$30.8M	Buy	9,250,055 +4,118,055	+80%	+$21.2M	1.03%	22
2024 Q4	$38M	Buy	5,132,000 +600,000	+13%	+$5.56M	1.23%	17
2024 Q3	$42.6M	Buy	4,532,000 +400,000	+10%	+$3.79M	1.49%	15
2024 Q2	$33.1M	Buy	4,132,000 +2,731,688	+195%	+$29.3M	1.27%	17
2024 Q1	$20.8M	Sell	1,400,312 -735,209	-34%	-$8.56M	1.06%	20
2023 Q4	$17.4M	Sell	2,135,521 -335,000	-14%	-$1.75M	0.58%	19
2023 Q3	$11.2M	Buy	2,470,521 +593,707	+32%	+$3.88M	0.4%	31
2023 Q2	$13.2M	Sell	1,876,814 -185,000	-9%	-$1.32M	0.6%	22
2023 Q1	$12.6M	Hold	2,061,814	–	–	0.71%	26
2022 Q4	$13.2M	Buy	2,061,814 +1,125,814	+120%	+$8.79M	0.91%	19
2022 Q3	$8.97M	Sell	936,000 -689,000	-42%	-$7.95M	0.87%	21
2022 Q2	$17.9M	Buy	1,625,000 +920,000	+130%	+$12.1M	1.88%	11
2022 Q1	$11.7M	Buy	705,000 +180,000	+34%	+$2.78M	1.51%	15
2021 Q4	$10M	Buy	+525,000	New	+$11.6M	1.33%	13

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Long Focus Capital Management's IOVA Position: Q1 2026 in Review

Long Focus Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 76% in Q1 2026, selling an estimated $20.8M and leaving 2,100,000 shares worth $7.37M. The position accounts for 0.19% of the portfolio, ranked #73.

Long Focus Capital Management first reported a position in IOVA in Q4 2021 and has held it in 18 quarters since. The position peaked at $42.6M in Q3 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Long Focus Capital Management held 2,100,000 shares of Iovance Biotherapeutics worth $7.37M as of Q1 2026.
Long Focus Capital Management sold 6,500,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $20.8M.
Iovance Biotherapeutics made up 0.19% of Long Focus Capital Management's portfolio in Q1 2026, its #73 holding.
Long Focus Capital Management first reported a position in Iovance Biotherapeutics in Q4 2021 and has held it in 18 quarters since.
Long Focus Capital Management's Iovance Biotherapeutics position peaked at $42.6M in Q3 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Long Focus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.